Oncologica is a leading contract research organization specializing in small and large end-to-end bioinformatic CRO laboratory services. We offer bioanalytical clinical contract research to aid drug and targeted medicine innovation through our expertise in genetic cell-based assays, molecular biomarkers and immunogenicity services.
We work as a collaborative CRO partner to deliver integrated bioanalytical contract research solutions for your genomic sequencing needs. We excel in bioinformatics contract research where extensive sequencing capabilities and accurate detection of variants are required.
- Human genetics research partner
- Outsource genetic studies
- Bioanalytical pre-clinical contract research
- Drug manufacturing bioanalytical research
- UK based genetic CRO



Genomic Sequencing Services
Oncologica sequencing capabilities are suitable for:
- Rare disease studies
- Cancer exome analysis
- Complex disease genomics
- Translational research
RNA Sequencing Services
Our highly experienced bioinformatics team utilise lab sequencing and a leading genomic data library, for analysis and interpretation of:
- Gene expression
- Transcriptome analysis
- RNA sequencing services



Sequencing for the Microbiome
Our wide range sequencing capabilities allows our researchers to sequence all given genomic DNA in a complex sample. This provides valuable insights into community biodiversity and function. The sequencing data can be used for metagenomic assembly, function and gene resistance profiling.
Bacterial RNA Sequencing
Oncologica Sequencing provides bacterial RNA sequencing, which can identify and compare bacterial community in a sample by sequencing regions of the bacterial 16s rRNA gene.
- Access Oncologica’s large database of genomic data
- Undertake bioinformatic analysis for taxonomy assignment
Research Papers

Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma
Published: March 25, 2022 DOI: https://doi.org/10.1371/journal.pone.0245817
Gareth H Williams, Alexander Llewelyn, Robert Thatcher, Keeda-Marie Hardisty, Marco Loddo

SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
EClinical Medicine by the Lancet Published:July 14, 2021 DOI: https://doi.org/10.1016/j.eclinm.2021.101021
Gareth H Williams, Alexander Llewelyn, Ruben Brandao, Kaiya Chowdhary,Keeda-Marie Hardisty, Marco Loddo (2021)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Front Oncol. 2021; 11: 686776. Published online 2021 Jun 28. doi: https://doi.org/10.3389/fonc.2021.686776
Alfredo Molteni, Alice Bruson, Carla Strina, Carlo Azzini, Daniele Generali, Davide Cerra, Elena Marasco, Elisa Zago, Fabiola Giudici, Francesco Schettini, Gareth H Williams, Giovanni Scambia, Giuseppina Barbieri, Giuseppina Ferrero, Ida Paris, Luciano Xumerle, Manuela Milani, Marco Loddo, Marco Ungari, Maria Chiara Lazzari, Maria Rosa Cappelletti, Marianna Sirico, Nicoletta Ziglioli, Ottavia Bernocchi, Sergio Aguggini, Silvia Paola Corona, Valeria Cervoni

The actionable genomic mutational landscape in solid tumours
J Clin Oncol 38: 2020 (suppl; abstr e13642) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13642
Loddo M, Hardisty KM, Thatcher RP, Haddow TE, Williams GH (2020)

Immunofocus-PD-L1 high throughput quantitative next generation sequencing assay
J Clin Oncol 38: 2020 (suppl; abstr e13521) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13521
Williams GH, Thatcher RP, Haddow TE, Hardisty KM, Loddo M (2020)

Druggable fusion gene landscape in solid tumors
J Clin Oncol 38: 2020 (suppl; abstr e13517) DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e13517
Williams GH, Thatcher RP, Nevado B, Haddow TE, Hardisty KM, Loddo M (2020)